H.U. GROUP HOLDINGS INC. Products & Brands - Key Offerings and Insights

Products

Category

Product

Brand

Description

Alzheimer's Disease Therapeutics and Diagnostics (PHM062E)

Lumipulse G β-Amyloid Ratio (1-42/1-40)

A CSF based FDA approved IVD that combines the results of Lumipulse G β-Amyloid 1-42 and Lumipulse G β-Amyloid 1-40 assays into a ratio of β-amyloid 1-42 to β-amyloid 1-40 concentrations using the Lumipulse G1200 System. Results must be interpreted in conjunction with other patient clinical information.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.